Dallas VA Medical Center
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Dallas VA Medical Center sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Dallas VA Medical Center: 20 sponsored US clinical trials, 2 recruiting.
Dallas VA Medical Center sponsors 20 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 13 completed. 3 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Esophagus Squamous Cell Carcinoma, with 1 trials.
Top-decile sponsor footprint
Dallas VA Medical Center ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
NCT04244630
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
NCT04018872
Home-based Walking Program With Smart Devices
NCT04113057
Misoprostol for Spinal Stenosis
NCT04611464
Mixed Reality Based System to Manage Phantom Pain Phantom Pain for Patients With Lower Limb Amputation
NCT04529083
Epidural Lavage Study for Lumbar Stenosis
NCT03511053
Healing of the Esophageal Mucosa After RFA of Barrett's Esophagus
NCT02688114
Impact of Hepatitis C Therapy and Bone Health
NCT03221582
Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition
NCT02579460
The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis
NCT01733810
Effects of Cerebral Protection With Filters vs. Flow Reversal on Cerebral Embolization After Carotid Artery Stenting
NCT01414387
Continuous Versus Conventional Volume Management During CRRT (Continuous Renal Replacement Therapy)
NCT01405092
Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study
NCT01647568
Defining the Utility of PET/CT in the Follow-up of Patients With Solid Tumors
NCT00954148
Exacerbating Factors in Inflammatory Bowel Disease
NCT01405105
Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients
NCT00677300
Effects of Carotid Stent Design on Cerebral Embolization
NCT00830232
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
NCT01404832
Minimization of Surgical Site Infections for Pts Undergoing Colorectal Surgery
NCT00953784
Prone Versus Left-sided Colonoscopy in Obese Patients
NCT01616602
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 4 | 3 |
What is open in the Dallas VA Medical Center pipeline
2 recruiting of 20 indexed (10% open); 13 completed (65%).
Phase mix: 3 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Esophagus Squamous Cell Carcinoma (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dallas VA Medical Center: open-pipeline peers nationwide
Peers matched on 20 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Dallas VA Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
- Ascension Health · 10% recruiting · 10 trials
Related
What to do with this Dallas VA Medical Center page
20 registered trials is a research-attention snapshot, not an endorsement of Dallas VA Medical Center or any single study.
- 2 of Dallas VA Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Esophagus Squamous Cell Carcinoma is the condition Dallas VA Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Esophagus Squamous Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dallas VA Medical Center pipeline card: 20 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.